Biotechnology

Landmark Liver Fibrosis Research Published in Cell, Cloud-Clone Aids ROCK2-Targeted Drug TDI01 Development

June 16, 2026 3:00 PM

In April 2026, a groundbreaking study-Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis-was published online in the prestigious international journal Cell. This research reveals for the first time that selective upregulation of ROCK2 in liver endothelial cells and perivascular hepatic stellate cells serves as a core mechanism driving the progression of liver fibrosis. The study has successfully led to the...

Read more

Everything Leaves A Trace: eDNA Technology Empowers Environmental Protection in China

June 16, 2026 4:33 AM

Since 2021, the China Zhi Gong Party has been carrying out a Yangtze River eco-environmental protection project in partnership with east China's Anhui Province. Faced with the complex challenge of river basin management, the party's central committee has leveraged its intellectual resources, bringing together a think tank of leading experts to launch a five-year "science and technology empowerment" initiative across the Jianghuai region, the...

Read more

Lifeloc Completes SpinDetect(TM) Disk Production Tooling, Commissions Cleanroom, and Outlines Staged Commercial Rollout

June 15, 2026 4:18 PM

Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, today provided an update on its SpinDetect™ Centrifugal Drug Analyzer program and its core breath alcohol business. Lifeloc has completed the production mold for the SpinDetect consumable test disks and produced first-article disks, which have undergone initial testing. Minor mold modifications identified...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

June 15, 2026 11:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)...

Read more

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

June 15, 2026 6:40 AM

Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract. The commercial-stage precision medicines company was just granted orphan drug exclusivity by the FDA for PAPZIMEOS™ (zopapogene imadenovec-drba), its treatment for RRP, a disease that typically requires patients to undergo...

Read more

Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS

June 15, 2026 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Data continue to demonstrate prolonged durability of response, with median duration of CR reaching 16.1 months in frontline HR‑MDS, supporting the upcoming initiation of the Phase 2b trial Median duration of Complete Remission (CR) in treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) extended to 16.1 months with bexmarilimab + azacitidine Frontline HR-MDS treatment achieved an 85% Overall...

Read more

Faron Pharmaceuticals Ltd: Holding(s) In Company

June 11, 2026 10:45 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if...

Read more

Faron Pharmaceuticals Ltd: Registration of Treasury Shares

June 11, 2026 10:25 AM

Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, as announced on 28 May 2026, issued 21,469,427 treasury shares to the Company itself without consideration to further prepare for any future conversions of the First and Second Tranche of Bonds. In total, 21,469,427 new Treasury Shares in the Company have on 8 June 2026 been registered in the Finnish Trade...

Read more

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

June 11, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's dementia has reached the Company's previously disclosed target enrollment of 146 patients, with 146 participants randomized at baseline. The Company's prior enrollment updates described progress toward this 146-patient target. Based on observed and potential attrition between...

Read more

BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

June 11, 2026 2:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced new clinical data from the BI-1206 triplet combination in relapsed/refractory (R/R) non-Hodgkin's lymphoma (NHL) to be presented in a poster at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. The poster summarizes key efficacy, safety,...

Read more

BioInvent's TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

June 11, 2026 2:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that clinical data from its ongoing Phase 2a trial evaluating BI-1808, its novel anti-TNFR2 monoclonal antibody, in patients with advanced CTCL is being presented at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden in a poster titled "Targeting TNFR2 with BI-1808 with or...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

June 10, 2026 1:00 PM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the issuer: Faron Pharmaceuticals Oy 2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights ☒ An acquisition or disposal of financial instruments ☐ An event changing the breakdown...

Read more

Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency

June 10, 2026 9:20 AM

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(Nasdaq Stockholm:EGTX), an innovative pharmaceutical company focused on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs, today announced the re-airing of a special episode of Behind the Mystery™, a television series featured on The Balancing Act®, which is broadcast nationally in the U.S. on the Lifetime...

Read more

AbTherx Expands Platform and Leadership Team to Unlock Antibody Discovery for Multispecifics, Enzymes, GPCRs, and Ion Channels

June 10, 2026 6:00 AM

AbTherx, Inc., a privately held biotechnology company focused on accelerating the discovery of next-generation antibody therapeutics, today announced an expansion of its proprietary Atlas™ Mouse technologies and leadership team as it sharpens of its discovery lens towards multispecifics and previously undruggable targets. The company is powering this new phase of growth with an expanded common light chain technology portfolio, a novel VHH...

Read more

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

June 9, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.50 per share. According to Ascendiant, the updated report highlights the Company's clinical progress and states that additional clinical data and progress...

Read more

Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares

June 9, 2026 6:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing high-potential drug candidates for diseases with significant unmet medical needs through a disciplined pharmaceutical development platform and focused subsidiary companies, today announced that its directors and officers have settled C$1,372,761.20 in accrued management and director fees through the issuance of 12,749,643 common shares of...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

June 8, 2026 12:50 PM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares: Faron Pharmaceuticals Oy 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer X 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of...

Read more

eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants

June 8, 2026 9:00 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant. The Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares...

Read more

NGD Infection Prevention Launches the NGD200: The First Automated Bacterial Sample Preparation System Purpose-Built for the Hospital Microbiology Lab

June 8, 2026 9:00 AM

NGD Infection Prevention announced today that its automated sequence-based infection transmission detection system is now compatible with Oxford Nanopore long-read sequencing. The automation, throughput and simplicity of use of the NGD200 sample preparation robotic system and NGD's integrated automated bioinformatics are now all available for Nanopore sequencing. Infection prevention teams increasingly recognize that comparing the whole genome...

Read more

Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate

June 8, 2026 8:32 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC® in Europe, where it has CE Mark approval. The hands-on training program is designed to train...

Read more